@article {Tyner2021.10.20.21265171, author = {Harmony L. Tyner and Jefferey L Burgess and Lauren Grant and Manjusha Gaglani and Jennifer L. Kuntz and Allison L. Naleway and Natalie J. Thornburg and Alberto J. Caban-Martinez and Sarang K. Yoon and Meghan K. Herring and Shawn C. Beitel and Lenee Blanton and Janko Nikolich-Zugich and Matthew S. Thiese and Jessica Flores Pleasants and Ashley L. Fowlkes and Karen Lutrick and Kayan Dunnigan and Young M.Yoo and Spencer Rose and Holly Groom and Jennifer Meece and Meredith G. Wesley and Natasha Schaefer-Solle and Paola Louzado-Feliciano and Laura J. Edwards and Lauren E. W. Olsho and Mark G. Thompson}, title = {Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection}, elocation-id = {2021.10.20.21265171}, year = {2021}, doi = {10.1101/2021.10.20.21265171}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Data on the development of neutralizing antibodies against SARS-CoV-2 after SARS-CoV-2 infection and after vaccination with messenger RNA (mRNA) COVID-19 vaccines are limited.Methods From a prospective cohort of 3,975 adult essential and frontline workers tested weekly from August, 2020 to March, 2021 for SARS-CoV-2 infection by Reverse Transcription- Polymerase Chain Reaction (RT-PCR) assay irrespective of symptoms, 497 participants had sera drawn after infection (170), vaccination (327), and after both infection and vaccination (50 from the infection population). Serum was collected after infection and each vaccine dose. Serum- neutralizing antibody titers against USA-WA1/2020-spike pseudotype virus were determined by the 50\% inhibitory dilution. Geometric mean titers (GMTs) and corresponding fold increases were calculated using t-tests and linear mixed effects models.Results Among 170 unvaccinated participants with SARS-CoV-2 infection, 158 (93\%) developed neutralizing antibodies (nAb) with a GMT of 1,003 (95\% CI=766-1,315). Among 139 previously uninfected participants, 138 (99\%) developed nAb after mRNA vaccine dose-2 with a GMT of 3,257 (95\% CI = 2,596-4,052). GMT was higher among those receiving mRNA-1273 vaccine (GMT =4,698, 95\%CI= 3,186-6,926) compared to BNT162b2 vaccine (GMT=2,309, 95\%CI=1,825-2,919). Among 32 participants with prior SARS-CoV-2 infection, GMT was 21,655 (95\%CI=14,766-31,756) after mRNA vaccine dose-1, without further increase after dose- 2.Conclusions A single dose of mRNA vaccine after SARS-CoV-2 infection resulted in the highest observed nAb response. Two doses of mRNA vaccine in previously uninfected participants resulted in higher nAb to SARS-CoV-2 than after one dose of vaccine or SARS- CoV-2 infection alone. Neutralizing antibody response also differed by mRNA vaccine product.Main Point Summary One dose of mRNA COVID-19 vaccine after previous SARS-CoV-2 infection produced the highest neutralizing antibody titers; among those without history of infection, two doses of mRNA vaccine produced the most robust response.Competing Interest StatementAllison Naleway receives research funding from Pfizer and Vir Biotechnology and Jennifer Kuntz receives research funding from Pfizer, Novartis, and Vir Biotechnology for unrelated studies. All other authors: No conflicts. Funding StatementThis work was supported by the Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases [contracts 75D30120R68013 to Marshfield Clinic Research Institute, 75D30120C08379 to the University of Arizona, and 75D30120C08150 to Abt Associates].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study is governed by Centers for Disease Control and Prevention IRB review board and gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript}, URL = {https://www.medrxiv.org/content/early/2021/10/26/2021.10.20.21265171}, eprint = {https://www.medrxiv.org/content/early/2021/10/26/2021.10.20.21265171.full.pdf}, journal = {medRxiv} }